- Last edited on July 18, 2023
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | Previous revision | ||
|
cl:0-autoimmune-encephalitis:hashimotos [on August 26, 2019] |
cl:0-autoimmune-encephalitis:hashimotos [on July 6, 2020] |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | ====== Hashimoto's Encephalitis ====== | + | ====== Hashimoto's Encephalitis (Steroid Responsive Encephalopathy Associated with Autoimmune Thyroiditis [SREAT]) ====== |
| {{INLINETOC}} | {{INLINETOC}} | ||
| ===== Primer ===== | ===== Primer ===== | ||
| Line 25: | Line 25: | ||
| The clinical presentation of HE can include seizures, myoclonus, hallucinations, and stroke-like episodes with normal or non-specific CSF and brain MRI abnormalities. | The clinical presentation of HE can include seizures, myoclonus, hallucinations, and stroke-like episodes with normal or non-specific CSF and brain MRI abnormalities. | ||
| </callout> | </callout> | ||
| + | <callout type="question" title="Controversial Diagnosis" icon="true"> | ||
| + | Hashimoto’s encephalopathy should be diagnosed only when a thorough clinical assessment has been performed, including comprehensive testing for well characterized neuronal antibodies, and ruling out other potential causes of encephalopathy or encephalitis. In essence, it should be a diagnosis of exclusion.</callout> | ||
| </WRAP> | </WRAP> | ||
| </WRAP> | </WRAP> | ||
| Line 50: | Line 52: | ||
| * [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2018852/|Gómez-Bernal, G. J., Reboreda, A., Romero, F., Bernal, M. M., & Gómez, F. (2007). A case of Hashimoto's encephalopathy manifesting as psychosis. Primary care companion to the Journal of clinical psychiatry, 9(4), 318.]] | * [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2018852/|Gómez-Bernal, G. J., Reboreda, A., Romero, F., Bernal, M. M., & Gómez, F. (2007). A case of Hashimoto's encephalopathy manifesting as psychosis. Primary care companion to the Journal of clinical psychiatry, 9(4), 318.]] | ||
| * [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693614/|Payer, J., Petrovic, T., Lisy, L., & Langer, P. (2012). Hashimoto encephalopathy: a rare intricate syndrome. International Journal of Endocrinology and Metabolism, 10(2), 506.]] | * [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693614/|Payer, J., Petrovic, T., Lisy, L., & Langer, P. (2012). Hashimoto encephalopathy: a rare intricate syndrome. International Journal of Endocrinology and Metabolism, 10(2), 506.]] | ||
| + | * [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714092/|Maroz, N., Bernhardt, N., & Chow, R. D. (2012). Autoimmune encephalopathy associated with thyroid autoantibodies as the cause of reversible cognitive impairment. Journal of community hospital internal medicine perspectives, 2(1), 11453.]] | ||
| + | * [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209691/|Anand, K. S., Garg, J., Verma, R., & Chakraborty, A. (2014). Hashimoto's encephalitis: Unusual cause of reversible dementia. Journal of family medicine and primary care, 3(3), 284.]] | ||
| <WRAP group> | <WRAP group> | ||